Le Lézard
Classified in: Health, Science and technology
Subjects: PLW, MAT

MMJ International Holdings Files US Patent Prior To FDA Study For Cannabinoid Treatment Medicine



RESTON, Va., Jan. 3, 2018 /PRNewswire-PRWeb/ -- MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, today announced that it has filed another patent invention with the United States Patent and Trademark Office that relates to pharmaceutical compounds and methods for treating and/or preventing symptoms associated with cannabinoid responsive diseases and disorders, such as Multiple Sclerosis (MS), and Huntington's disease (HD).

MMJ BioScience's disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amounts of a pharmaceutical compound containing cannabinoids to Multiple Sclerosis (MS) and Huntington's (HD) disease patients in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.The MMJ BioScience has filed these patents to protect the delivery of its MMJ BioScience® product formulation for its upcoming multiple sclerosis FDA study which is progressing through the Federal Drug Administrations (FDA) regulatory process.

Dr. Bianca Weinstock-Guttman, MMJ BioScience's principal investigator, is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

In late 2017 MMJ BioScience had submitted an application with the United States Food and Drug Administration (FDA) for approval of a new pharmaceutical drug. Unlike other cannabis-type medicines, MMJ BioScience's medicine is plant derived. When approval is received from the FDA the new medicine would be on sale across America as an approved drug.

MMJ BioScience's expected approval by the FDA for its new medicine would have a major impact on the state to state emerging cannabis industry which is not federally legal. Most recently the FDA had issued several cease and desist letters to firms that are marketing unapproved cannabinoid products. Whereas non-pharmaceutical companies cannot export their products across state lines, MMJ BioScience would be able to sell its medicine in pharmacies once prescribed by physicians.

MMJ BioScience's discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.

 

SOURCE MMJ International Holdings


These press releases may also interest you

at 11:00
LEXINGTON, Mass., Sept. 23, 2018 /PRNewswire-PRWeb/ -- Ninestone Corporation, a management consulting firm that specializes in working with healthcare, small business and non-profit organizations, announced today their selection as an approved vendor...

at 10:00
Compare-autoinsurance.org has recently published a list with the most common car insurance myths and explains why each of them is false.  Like many other industries, auto insurance is also plagued by some myths, many of them spread by people with...

at 09:00
MRO, a leader in the secure, compliant and efficient exchange of protected health information (PHI), announced today the general availability of its business office medical record attachment solution. Specialized services and technology enable...

at 09:00
Cheapquotesautoinsurance.com has released a new blog post that explains how drivers can get cheap car insurance quotes and save money. Insurance quotes represent basic estimates and offer the average costs for a coverage plan. But when used...

at 08:45
Central Learning, a web-based coding assessment and education application, released the results of the 3rd annual nationwide ICD-10 coding contest. Central Learning is part of the Pena4, Inc. suite of health information and revenue cycle technology...

at 08:00
Compare-autoinsurance.org (http://compare-autoinsurance.org/) is a top auto insurance brokerage website, providing car insurance quotes online from trustworthy agencies all over the United States. Drivers can access free car insurance quotes and...




News published on 3 january 2018 at 13:00 and distributed by: